Clinical trial Recruiting at 1 site Observational

Finding genetic variants in patients with heart failure undergoing breast cancer treatment

Official title: Exploratory Next Generation Sequencing to Identify Causative Variants for Therapy-Induced Congestive Heart Failure From Breast Cancer Study E5103 Germline DNA Samples

Run by National Cancer Institute (NCI) · NCT02610426 · Data updated 2026-11-12

This study is trying to find genetic changes in patients who have heart failure while being treated for breast cancer to help improve future treatments and understand their risks better.

Quick facts

Study typeObservational
SexAll
Enrollment162 (estimated)
SponsorNational Cancer Institute (NCI)
NIH
Drugs / interventionsbevacizumab
Locations1 site (Boston, Massachusetts)
StatusRecruiting
StartedMarch 25, 2014
Main results expectedJanuary 1, 2100
Study endsJanuary 1, 2100
Registry record updatedMarch 27, 2026
Trial IDNCT02610426 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include European American patients with available DNA who have developed congestive heart failure after breast cancer treatment, as well as African American patients with specific heart function criteria.

Probably not a fit

Patients who do not have a genetic predisposition to heart failure or who are not undergoing treatment for breast cancer may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research focuses on using whole exome sequencing to identify genetic variants in germline DNA samples from patients who have congestive heart failure while receiving treatment for breast cancer. The study aims to analyze previously collected DNA samples to uncover rare variants that may influence the risk of developing heart failure in these patients. By understanding the genetic changes associated with heart failure, the research could lead to better biomarkers and treatment strategies for affected individuals.

Why it matters

Potential benefit: If successful, this study could help identify genetic markers that predict heart failure risk in breast cancer patients, leading to improved patient management.

How similar studies have gone: Other studies utilizing whole exome sequencing have shown promise in identifying genetic factors related to various conditions, suggesting potential success for this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* European American patients with DNA available
* European American patients who developed CHF and patients who did not develop CHF following a full course of treatment with an anthracycline and bevacizumab
* African American cases (based on a drop in left ventricular ejection fraction \[LVEF\] \< 50 or a drop from baseline \> 20 points) and African American controls

Where it's running

  • Eastern Cooperative Oncology Group
    Boston, Massachusetts, United States
    Recruiting

Study contacts

  • Principal investigator: Bryan P Schneider — Eastern Cooperative Oncology Group

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.